Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus with Appointment of Four Key Leaders in the Bioscience Industry to Its Board of Directors
The Fitzsimons Redevelopment Authority (FRA) is adding four of the area's most well-known and successful leaders in the Bioscience Industry to its Board of Directors. Change in board composition is the result of a strategic refocus for the FRA, and those recently appointed to the board include: Donald M. Elliman, Jr.; William Freytag, PhD; James C. T. Linfield; and David Perez.
Aurora, CO, November 15, 2011 --(PR.com)-- In a strategic effort to refocus and strengthen its organization, the Fitzsimons Redevelopment Authority (FRA) has completed a regimen of planning to make adjustments in the direction, roles, responsibilities and allocation of resources going forward. The announcement is made by Denise Brown, FRA Interim Executive Director, who says, "Our first tactic in refocus involves augmenting our board of directors with four of the area's most well-known and successful leaders in the bioscience industry to help build programs and services to attract bioscience companies to relocate to Colorado and keep growing Colorado-based bioscience companies here, adding to our employment base. Modifying the board accordingly was approved in a recent board action."
Joining the FRA Board are Donald M. Elliman, Jr., Executive Director of the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology and current Director and former Chair of the Children's Hospital Colorado Board of Directors; William Freytag, PhD, former Chairman and CEO of Myogen, Inc.; James C. T. Linfield, Partner-in-Charge of the Colorado office of Cooley LLP; and David Perez, President and Chief Executive Officer of CaridianBCT, becoming TerumoBCT.
Brown continues, "We're very pleased to welcome our new board members. These leaders are actively involved the bioscience community - locally, nationally and internationally - and maintain those critical relationships with entrepreneurs, companies and research groups required to guide the FRA through its next phase of growth. This is the first time the FRA has had bioscience executives on its board.
"As the Fitzsimons site has matured, it's become clear to the FRA board that it needed to do more to support the growth of early-stage Colorado bioscience companies, especially those developing technologies from Colorado's research institutions, with an emphasis on those technologies developed at the Anschutz Medical Campus. Hence, the FRA is now addressing the critical need to bring bioscience-focused leadership to the board process in building new corporate partnerships and leveraging the strength of the Anschutz Medical Campus and the FRA's real estate development partner, the Forest City Science + Technology Group," Brown explains.
New FRA Board Members - Bioscience Industry Leadership
* Donald M. Elliman, Jr. (representing Children’s Hospital Colorado on the FRA Board) -- In February of 2011, Mr. Elliman was named Executive Director of the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology. From June of 2009 to January of 2011, Don served as Chief Operating Officer for Colorado.
* William Freytag, PhD -- Dr. Freytag currently serves as a member of the board of directors for three health care companies: GlobeImmune, BaroFold, and BiOptix Inc. Dr. Freytag was Chairman and Chief Executive Officer of Aspreva Pharmaceuticals from July 2007 until its merger with Galenica AG in January 2008.
* James C. T. Linfield -- As Partner-in-Charge of the Colorado office of Cooley LLP, Mr. Linfield's practice focuses on representation of public and private technology companies and venture capital funds, with an emphasis on corporate finance, mergers and acquisitions and strategic alliances.
* David Perez -- As President and Chief Executive Officer of the combined businesses of CaridianBCT and Terumo Transfusion—soon to be Terumo BCT, Mr. Perez also serves as Chairman of Terumo Corporation’s Blood Management Business board.
Other FRA Board members include: Bruce Benson, President, University of Colorado; Bruce Schroffel, President, University of Colorado Hospital; John Shaw, Principal, McWhinney; Lilly Marks, Vice President for Health Affairs and Executive Vice Chancellor of the Anschutz Medical Campus; Dwight Rider, Principal, Freund Investments; and Councilwoman Melissa Miller from Aurora who will be joined by two other elected officials to be named by the Aurora City Council.
About Fitzsimons Redevelopment Authority
The FRA directs the commercial developments in the Fitzsimons Life Science District, along with its partner, Forest City Science + Technology Group. In this role, the FRA is dedicated to providing life science companies: an environment where they can thrive; success-enhancing resources like the District’s incubator facilities; and services that help form connections between private industry and the University of Colorado For more information, visit: http://www.fitzscience.com.
###
Contacts:
Vicki Jenings, CPM, Director of Business Relations, Fitzsimons Redevelopment Authority -http://www.fitzscience.com - 720-859-4108 - vjenings@colobio.com
Maggie Chamberlin Holben, APR, Principal - Absolutely Public Relations -
http://www.absolutelypr.com - 303-984-9801 and 303-669-3558 (cell), maggie@absolutelypr.com
Joining the FRA Board are Donald M. Elliman, Jr., Executive Director of the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology and current Director and former Chair of the Children's Hospital Colorado Board of Directors; William Freytag, PhD, former Chairman and CEO of Myogen, Inc.; James C. T. Linfield, Partner-in-Charge of the Colorado office of Cooley LLP; and David Perez, President and Chief Executive Officer of CaridianBCT, becoming TerumoBCT.
Brown continues, "We're very pleased to welcome our new board members. These leaders are actively involved the bioscience community - locally, nationally and internationally - and maintain those critical relationships with entrepreneurs, companies and research groups required to guide the FRA through its next phase of growth. This is the first time the FRA has had bioscience executives on its board.
"As the Fitzsimons site has matured, it's become clear to the FRA board that it needed to do more to support the growth of early-stage Colorado bioscience companies, especially those developing technologies from Colorado's research institutions, with an emphasis on those technologies developed at the Anschutz Medical Campus. Hence, the FRA is now addressing the critical need to bring bioscience-focused leadership to the board process in building new corporate partnerships and leveraging the strength of the Anschutz Medical Campus and the FRA's real estate development partner, the Forest City Science + Technology Group," Brown explains.
New FRA Board Members - Bioscience Industry Leadership
* Donald M. Elliman, Jr. (representing Children’s Hospital Colorado on the FRA Board) -- In February of 2011, Mr. Elliman was named Executive Director of the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology. From June of 2009 to January of 2011, Don served as Chief Operating Officer for Colorado.
* William Freytag, PhD -- Dr. Freytag currently serves as a member of the board of directors for three health care companies: GlobeImmune, BaroFold, and BiOptix Inc. Dr. Freytag was Chairman and Chief Executive Officer of Aspreva Pharmaceuticals from July 2007 until its merger with Galenica AG in January 2008.
* James C. T. Linfield -- As Partner-in-Charge of the Colorado office of Cooley LLP, Mr. Linfield's practice focuses on representation of public and private technology companies and venture capital funds, with an emphasis on corporate finance, mergers and acquisitions and strategic alliances.
* David Perez -- As President and Chief Executive Officer of the combined businesses of CaridianBCT and Terumo Transfusion—soon to be Terumo BCT, Mr. Perez also serves as Chairman of Terumo Corporation’s Blood Management Business board.
Other FRA Board members include: Bruce Benson, President, University of Colorado; Bruce Schroffel, President, University of Colorado Hospital; John Shaw, Principal, McWhinney; Lilly Marks, Vice President for Health Affairs and Executive Vice Chancellor of the Anschutz Medical Campus; Dwight Rider, Principal, Freund Investments; and Councilwoman Melissa Miller from Aurora who will be joined by two other elected officials to be named by the Aurora City Council.
About Fitzsimons Redevelopment Authority
The FRA directs the commercial developments in the Fitzsimons Life Science District, along with its partner, Forest City Science + Technology Group. In this role, the FRA is dedicated to providing life science companies: an environment where they can thrive; success-enhancing resources like the District’s incubator facilities; and services that help form connections between private industry and the University of Colorado For more information, visit: http://www.fitzscience.com.
###
Contacts:
Vicki Jenings, CPM, Director of Business Relations, Fitzsimons Redevelopment Authority -http://www.fitzscience.com - 720-859-4108 - vjenings@colobio.com
Maggie Chamberlin Holben, APR, Principal - Absolutely Public Relations -
http://www.absolutelypr.com - 303-984-9801 and 303-669-3558 (cell), maggie@absolutelypr.com
Contact
Fitzsimons Redevelopment Authority
Maggie Holben
303-984-9801
www.fitzscience.com
Maggie Holben
303-984-9801
www.fitzscience.com
Contact
Categories